ELECTROMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.62 USD | -1.15% |
|
-12.19% | +34.01% |
| May. 07 | Transcript : Electromed, Inc., Q3 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Electromed, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 28.67 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +34.01% | 127M | C | ||
| +7.01% | 217B | B | ||
| +11.01% | 190B | B- | ||
| +19.20% | 143B | B- | ||
| +30.79% | 111B | A- | ||
| +1.48% | 64.59B | A- | ||
| +13.95% | 52.36B | B+ | ||
| -0.16% | 48.45B | B+ | ||
| -6.20% | 38.03B | A | ||
| +0.91% | 35.61B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ELMD Stock
- Ratings Electromed, Inc.
